NCT04205006

Brief Summary

We undertook the STROKE-CARD trial (NCT02156778) between 2014 and 2018 with follow-up until 2019 to evaluate the efficacy of the Post-Stroke disease-management program STROKE-CARD care. To further investigate the long-term efficacy of STROKE-CARD care all participants of the original trial will be invited for a Long-term in Person follow-up (3 - 6 years).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2019

Typical duration for all trials

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 13, 2019

Completed
3 days until next milestone

Study Start

First participant enrolled

December 16, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 19, 2019

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2022

Completed
Last Updated

August 30, 2022

Status Verified

April 1, 2022

Enrollment Period

2.9 years

First QC Date

December 13, 2019

Last Update Submit

August 29, 2022

Conditions

Keywords

ischemic strokesecondary preventiontransient ischemic attackdisease management

Outcome Measures

Primary Outcomes (4)

  • The composite CVD outcome: nonfatal stroke (ischemic or hemorrhagic)

    Recurrent stroke

    through study completion, an average of 4,5 years

  • The composite CVD outcome: nonfatal myocardial infarction

    Major recurrent (post-discharge) cardiac event

    through study completion, an average of 4,5 years

  • The composite CVD outcome: vascular death

    death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, stroke, cardiovascular procedures, and death due to other CV causes.

    through study completion, an average of 4,5 years

  • self-reported health-related quality of life

    quantified with the European Quality of Life 5-Dimensions 3-Levels (EQ-5D-3L) overall health utility score14 with rescaled European visual analogue scale weights.

    through study completion, an average of 4,5 years

Secondary Outcomes (4)

  • The composite outcome of stroke/TIA

    through study completion, an average of 4,5 years

  • all-cause mortality

    through study completion at long term follow up visit, an average of 4,5 years

  • EQ-ED-3L

    through study completion at long term follow up visit, an average of 4,5 years

  • Proportions of participants achieving target levels of risk factors in each trial arm of the previous STROKE-CARD trial.

    through study completion at long term follow up visit, an average of 4,5 years

Study Arms (1)

STROKE CARD Cohort

Consecutive patients treated at the Department of Neurology of the University Hospital Innsbruck with ischemic stroke or high-risk TIA between 2013 and 2018 and enrolled in the Stroke Card trial, (except for those who aborted the previous trial).

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients from the STROKE-CARD trial (n=2149) will be contacted by phone or mail for possible enrolment in the study. The STROKE-CARD cohort included consecutive patients with acute ischaemic stroke or TIA (ABCD2-Score ≥ 3) admitted to one of the two study centres (Medical University of Innsbruck, Hospital St. John's of God Vienna) between 2014 and 2018.

You may qualify if:

  • Written informed consent

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Medical University of Innsbruck, Department of Neurology

Innsbruck, Tyrol, 6020, Austria

Location

Hospital St. John's of God

Vienna, 1020, Austria

Location

Related Publications (4)

  • Toell T, Boehme C, Mayer L, Krebs S, Lang C, Willeit K, Prantl B, Knoflach M, Rumpold G, Schoenherr G, Griesmacher A, Willeit P, Ferrari J, Lang W, Kiechl S, Willeit J. Pragmatic trial of multifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack -study protocol. BMC Neurol. 2018 Nov 6;18(1):187. doi: 10.1186/s12883-018-1185-2.

  • Boehme C, Toell T, Mayer-Suess L, Domig L, Pechlaner R, Willeit K, Tschiderer L, Seekircher L, Willeit P, Griesmacher A, Knoflach M, Willeit J, Kiechl S. The dimension of preventable stroke in a large representative patient cohort. Neurology. 2019 Dec 3;93(23):e2121-e2132. doi: 10.1212/WNL.0000000000008573. Epub 2019 Oct 31.

  • Karisik A, Dejakum B, Moelgg K, Granna J, Felicetti S, Pechlaner R, Mayer-Suess L, Toell T, Buergi L, Scherer L, Willeit K, Heidinger M, Lang C, Ferrari J, Krebs S, Kleyhons R, Resch H, Willeit J, Seekircher L, Tschiderer L, Willeit P, Sykora M, Schett G, Lang W, Knoflach M, Kiechl S, Boehme C. Incidence, characteristics, and consequences of fractures after acute ischemic stroke and TIA-A prospective cohort study. Int J Stroke. 2025 Oct;20(9):1141-1149. doi: 10.1177/17474930251345300. Epub 2025 May 20.

  • Boehme C, Domig L, Komarek S, Toell T, Mayer L, Dejakum B, Krebs S, Pechlaner R, Bernegger A, Mueller C, Rumpold G, Griesmacher A, Vigl M, Schoenherr G, Schmidauer C, Ferrari J, Lang W, Knoflach M, Kiechl S. Long-term outcome of a pragmatic trial of multifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack: study protocol. BMC Cardiovasc Disord. 2022 Aug 1;22(1):347. doi: 10.1186/s12872-022-02785-5.

Biospecimen

Retention: SAMPLES WITH DNA

Serum and whole blood sample.

MeSH Terms

Conditions

Ischemic StrokeIschemic Attack, Transient

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesBrain Ischemia

Study Officials

  • Stefan Kiechl, Prof. Dr.

    Medical University of Innsbruck, Austria, Department of Neurology

    PRINCIPAL INVESTIGATOR
  • Wilfried Lang, Prof. Dr.

    Hospital St. John's of God, Vienna, Austria, Department of Neurology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 13, 2019

First Posted

December 19, 2019

Study Start

December 16, 2019

Primary Completion

November 1, 2022

Study Completion

November 1, 2022

Last Updated

August 30, 2022

Record last verified: 2022-04

Data Sharing

IPD Sharing
Will not share

Locations